Children who have juvenile idiopathic arthritis (JIA) are first treated with non-steroidal anti-inflammatory drugs (NSAIDs) that often provide relief and reduce inflammation. NSAIDs are considered the first-line treatment for JIA. Second-line drug therapy-known interchangeably as disease-modifying antirheumatic drugs (DMARDs) and as slow-acting antirheumatic drugs (SAARDs)-for JIA may be recommended when a child continues to have joint pain, swelling, or both despite rest, exercise, use of NSAIDs, and physiotherapy.
DMARDs/SAARDs include azathioprine, cyclosporine, etanercept, methotrexate, and sulfasalazine.
DMARDs/SAARDs have a lot in common.
Although these medicines are often called "disease-modifying," it has been hard to prove that they truly prevent long-term joint damage. But they often relieve pain and swelling.
ByHealthwise StaffPrimary Medical ReviewerSusan C. Kim, MD - PediatricsBrian D. O'Brien, MD - Internal MedicineMartin J. Gabica, MD - Family MedicineKathleen Romito, MD - Family MedicineSpecialist Medical ReviewerJohn Pope, MD - Pediatrics
Current as ofOctober 10, 2017
Current as of: October 10, 2017
Susan C. Kim, MD - Pediatrics
& Brian D. O'Brien, MD - Internal Medicine & Martin J. Gabica, MD - Family Medicine & Kathleen Romito, MD - Family Medicine & John Pope, MD - Pediatrics
To learn more about Healthwise, visit Healthwise.org.
© 1995-2018 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.